EntreMed's ENMD-2076 Active in Solid and Hematological Cancers
ROCKVILLE, Md., Nov. 16 -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of data for the Phase 1 study for its Aurora A/angiogenic kinase inhibitor, E...
|
|
|
|
|
LCA Releases 5th National Report Card on Lung Cancer
Notes Some Improvements, But Passing Grades Still Lacking
WASHINGTON, Nov. 19 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) released its annual National Report Card on Lung Cancer, an overall assessment of efforts to reduce lung cancer's mortal...
|
|
|
|
|
|
|
CPRIT Responds to USPSTF Revised Mammography Screening Guidelines
AUSTIN, Texas -
The Cancer Prevention and Research Institute of Texas (CPRIT) announced
today at its quarterly board meeting that it will continue to support
mammography screening for women at average risk for breast cancer
beginning at age 40. This comes in response to a recent United State
|
Paisley, the Portuguese Water Dog, Will Soon Arrive at maurices
Sales Will Support the American Cancer Society/I/P
PDuluth, Minn. (Vocus) November 17, 2009 -- a href= https://secure.maurices.com/chatter/images/HOL_900ePaisley8x6.pdf onclick= linkClick( this.href ); target= _blank title= Paisley, the Portuguese Water Dog Paisley, the Portugues...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Med-Vision and Biologics Set to Co-Host a Cancer Management Workshop
TAMPA, Fla. -
The healthcare planning team of Med-Vision has partnered with the
premier cancer management company, Biologics, Inc., to present a Cancer
Management Workshop on Dec. 8 from 8 a.m. to 1 p.m. at the Tampa Club,
101 Kennedy Blvd., Suite 4200, Tampa. Continental
|
Enzon Presents Data at 2009 EORTC Meeting
BRIDGEWATER, N.J. -
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) presented data from its
pipeline programs at the 2009 EORTC-NCI-AACR (European Organization for
Research and Treatment of Cancer-National Cancer Institute-American
Association for Cancer Research) annual meeting in Boston, Massac
|
|
|
ImmunoCellular Therapeutics Issues Letter to Shareholders
LOS ANGELES -
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology
company that is focused on the development of novel immune-based cancer
therapies, issued the following Letter to Shareholders today:
Dear ImmunoCellular Therapeutics Shareholder:
|
|
|
|
|
|
|